Detalles de la búsqueda
1.
No excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy.
Br J Haematol
; 188(5): 685-691, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31612478
2.
Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients.
Br J Haematol
; 189(4): 661-671, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32017050
3.
Idelalisib in relapsed/refractory diffuse large B-cell lymphoma: results from a Nordic Lymphoma Group phase II trial.
Br J Haematol
; 196(2): 437-440, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34435356
4.
Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited-Field Radiotherapy.
J Clin Oncol
; 40(13): 1487-1496, 2022 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35077204
5.
Real-world data on treatment concepts in classical Hodgkin lymphoma in Sweden 2000-2014, focusing on patients aged >60 years.
EJHaem
; 2(3): 400-412, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-35844675
6.
Characteristics and outcome of patients with relapsed/refractory Hodgkin lymphoma following front-line escalated BEACOPP-based chemotherapy: a report from the Australasian Lymphoma Alliance.
Leuk Lymphoma
; 61(14): 3412-3416, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32856509
Resultados
1 -
6
de 6
1
Próxima >
>>